Klinische Wochenschrift

, Volume 66, Issue 8, pp 361–364

Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in cushing's syndrome

  • B. Allolio
  • H. M. Schulte
  • D. Kaulen
  • M. Reincke
  • C. Jaursch-Hancke
  • W. Winkelmann


We determined the adrenostatic potential of low-dose nonhypnotic etomidate in six patients with Cushing's syndrome (ectopic Cushing's syndrome,n=2; Cushing's disease,n=3; bilateral adrenal adenoma,n=1). Etomidate was given as a continuous infusion for 32 h in a dose of 2.5 mg/h (n=5) or 0.3 mg/kg/h (n=3), respectively. Saline was given during a control period. The responsiveness to exogenous ACTH was studied during placebo and 7 and 31 h after commencing etomidate by administration of 250 µg 1–24 ACTH i.v. Etomidate (2.5 mg/h) led to a consistent decrease in serum cortisol in all patients from a mean of 39.4±13.3 to 21.1±5.7 µg/dl after 7 h (P<0.05 compared with placebo). After 24 h cortisol was reduced further to a mean steady state concentration of 12.3±5.7 µg/dl (P<0.05). At the end of the infusion period the cortisol increase in response to ACTH was reduced but not abolished. In contrast, a dose of 0.3 mg/kg/h etomidate induced unresponsiveness of serum cortisol to exogenous ACTH within 7 h. However, sedation was observed in two out of three patients at this dose, while during etomidate in a dose of 2.5 mg/h no side effects were seen. We conclude that low-dose non-hypnotic etomidate reduces serum cortisol to within the normal range in patients with Cushing's syndrome. The possibility to dissociate the adrenostatic effect of etomidate from its hypnotic action, the absence of side effects, and the i.v. route suggest that etomidate in a dose of 0.04–0.05 mg/kg/h may become the drug of choice for rapid initial control of hypercortisolism.

Key words

Etomidate Cortisol ACTH Cushing's syndrome 



adrenocorticotrophic hormone


Cushing's disease


Cushing's syndrome


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Allolio B, Winkelmann W, Hipp FX (1980) Effect of meclastine, an H1-antihistamine, on plasma ACTH in adrenal insufficiency. Acta Endocrinol 96:98–101Google Scholar
  2. 2.
    Allolio B, Stuttmann R, Leonhard U, Fischer H, Winkelmann W (1984) Adrenocortical suppression by a single induction dose of etomidate. Klin Wochenschr 62:1014–1017Google Scholar
  3. 3.
    Allolio B, Dörr H, Stuttmann R, Knorr D, Engelhardt D, Winkelmann W (1985) Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH. Clin Endocrinol 22:281–286Google Scholar
  4. 4.
    Child DF, Burke CW, Burley DW, Rees LH, Fraser TR (1985) Drug control of Cushing's syndrome. Acta Endocrinol 82:330–341Google Scholar
  5. 5.
    De Coster R, Beerens D, Haelterman C, Wouters L (1985) Effects of etomidate on cortisol biosynthesis in isolated guinea-pig adrenal cells: comparison with metyrapone. J Endocrinol Invest 8:199–202Google Scholar
  6. 6.
    Engelhardt D, Stuttmann H, Jacob K, Dörr HG (1986) Influence of low-dose etomidate on adrenal and gonadal steroid hormone secretion in normal men. Acta Endocrinol [Suppl 274] 111:21–22Google Scholar
  7. 7.
    Fragen RJ, Shanks CA, Molteni A, Avram MJ (1984) Effects of etomidate on hormonal responses to surgical stress. Anesthesiology 61:652–656Google Scholar
  8. 8.
    Fry DE, Griffiths H (1984) The inhibition by etomidate of the 11β-hydroxylation of cortisol. Clin Endocrinol 20:625–629Google Scholar
  9. 9.
    Gärtner R, Albrecht M, Müller OA (1986) Effect of etomidate on hypercortisolism due to ectopic ACTH production. Lancet I:275Google Scholar
  10. 10.
    Hebron BS, Edbrooke DL, Newby DM, Mather SJ (1983) Pharmacokinetics of etomidate associated with prolonged i.v. infusion. Br J Anaesth 55:281–285Google Scholar
  11. 11.
    Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CRW, Besser GM (1977) Metyrapone in long-term management of Cushing's disease. Br Med J 2:215–217Google Scholar
  12. 12.
    Kenyon CJ, Young J, Gray CE, Fraser R (1984) Inhibition by etomidate of steroidogenesis in isolated bovine adrenal cells. J Clin Endocrinol Metab 58:947–949Google Scholar
  13. 13.
    Lambert A, Mitchell R, Forst J, Ratcliffe JG, Robertson WR (1983) Direct in vitro inhibition of adrenal steroidogenesis by etomidate. Lancet II:1085–1086Google Scholar
  14. 14.
    Loli P, Berselli ME, Tagliaferri M (1986) Use of ketoconazole in the treatment of Cushing's syndrome. J Clin Endocrinol Metab 63:1365–1370Google Scholar
  15. 15.
    Stalla GK, Stalla J, Huber M, Müller OA (1987) Ketoconazole inhibits cAMP generation and ACTH secretion in rat anterior pituitary cell culture. Acta Endocrinol [Suppl 283] 114:32–33Google Scholar
  16. 16.
    Thoren M, Adamson U, Sjöberg HE (1985) Aminoglutethimide and metyrapone in the management of Cushing's syndrome. Acta Endocrinol 109:451–457Google Scholar
  17. 17.
    Vanden Bossche H, Willemsens G, Cools W, Bellens D (1984) Effects of etomidate on steroid biosynthesis in subcellular fractions of bovine adrenals. Biochem Pharmacol 33:3861–3868Google Scholar
  18. 18.
    Voigt KH, Fehm HL, Reck R, Pfeiffer EF (1974) Spontaneous and stimulated secretion of Quso-extractable immunoassayable ACTH in man. Klin Wochenschr 52:516–521Google Scholar
  19. 19.
    Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman MD (1984) Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 310:1415–1421Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • B. Allolio
    • 1
  • H. M. Schulte
    • 2
  • D. Kaulen
    • 1
  • M. Reincke
    • 1
  • C. Jaursch-Hancke
    • 1
  • W. Winkelmann
    • 1
  1. 1.Medizinische Universitätsklinik II, Köln-MerheimGermany
  2. 2.I. Medizinische UniversitätsklinikKielGermany

Personalised recommendations